RU2019124709A - КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА - Google Patents
КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА Download PDFInfo
- Publication number
- RU2019124709A RU2019124709A RU2019124709A RU2019124709A RU2019124709A RU 2019124709 A RU2019124709 A RU 2019124709A RU 2019124709 A RU2019124709 A RU 2019124709A RU 2019124709 A RU2019124709 A RU 2019124709A RU 2019124709 A RU2019124709 A RU 2019124709A
- Authority
- RU
- Russia
- Prior art keywords
- domain
- monomer
- polypeptide
- igg1
- antigen binding
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims 37
- 239000000203 mixture Substances 0.000 title 1
- 239000000178 monomer Substances 0.000 claims 89
- 229920001184 polypeptide Polymers 0.000 claims 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims 50
- 102000036639 antigens Human genes 0.000 claims 34
- 108091007433 antigens Proteins 0.000 claims 34
- 230000035772 mutation Effects 0.000 claims 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443523P | 2017-01-06 | 2017-01-06 | |
| US62/443,523 | 2017-01-06 | ||
| PCT/US2018/012689 WO2018129397A1 (en) | 2017-01-06 | 2018-01-05 | Compositions and methods related to engineered fc-antigen binding domain constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019124709A true RU2019124709A (ru) | 2021-02-08 |
| RU2019124709A3 RU2019124709A3 (enExample) | 2021-12-21 |
Family
ID=62791385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019124709A RU2019124709A (ru) | 2017-01-06 | 2018-01-05 | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200040084A1 (enExample) |
| EP (1) | EP3565595A4 (enExample) |
| JP (1) | JP2020514301A (enExample) |
| AU (1) | AU2018205272A1 (enExample) |
| CA (1) | CA3049426A1 (enExample) |
| RU (1) | RU2019124709A (enExample) |
| WO (1) | WO2018129397A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210206857A1 (en) * | 2018-05-21 | 2021-07-08 | Bioprocessia Technologies Llc | Multivalent protein complexes |
| BR112021000392A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados |
| AU2019300020A1 (en) * | 2018-07-11 | 2021-02-18 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered Fc-antigen binding domain constructs |
| EP3820910A4 (en) * | 2018-07-11 | 2022-06-22 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATING TO ENGINEERED FC ANTIGEN-BINDING DOMAIN CONSTRUCTS |
| BR112021000415A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados |
| BR112021016829A2 (pt) | 2019-02-26 | 2021-10-19 | Pieris Pharmaceuticals Gmbh | Proteínas de fusão, molécula de ácido nucleico, métodos de produção, de ativar simultaneamente as vias de sinalização, de coestimular células t, de induzir uma resposta de linfócitos e de induzir o aumento da citólise, composição farmacêutica e método para prevenir, melhorar ou tratar cânceres |
| CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
| EP4031166A1 (en) * | 2019-09-18 | 2022-07-27 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 |
| KR20230060546A (ko) | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| WO2024219897A1 (ko) | 2023-04-21 | 2024-10-24 | 상트네어바이오사이언스 주식회사 | 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| WO2024219894A1 (ko) | 2023-04-21 | 2024-10-24 | 상트네어바이오사이언스 주식회사 | 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5598894B2 (ja) * | 2006-03-03 | 2014-10-01 | 学校法人東京理科大学 | 生物活性を強化した抗体改変体 |
| CA2685698A1 (en) * | 2007-04-30 | 2008-11-13 | Centocor Ortho Biotech Inc. | Anti-tissue factor antibodies and compositions with enhanced effector function |
| BR112013019975A2 (pt) * | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" |
| MX2014001019A (es) * | 2011-07-27 | 2014-05-13 | Glaxo Group Ltd | Dominios variables singulares anti-vgf fusionados con dominios de fc. |
| WO2014138449A1 (en) * | 2013-03-06 | 2014-09-12 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
| US10858417B2 (en) * | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| IL286367B2 (en) * | 2014-05-02 | 2023-03-01 | Momenta Pharmaceuticals Inc | Compositions and methods relating to engineered fc constructs |
-
2018
- 2018-01-05 US US16/474,572 patent/US20200040084A1/en not_active Abandoned
- 2018-01-05 RU RU2019124709A patent/RU2019124709A/ru unknown
- 2018-01-05 EP EP18735797.5A patent/EP3565595A4/en not_active Withdrawn
- 2018-01-05 AU AU2018205272A patent/AU2018205272A1/en not_active Abandoned
- 2018-01-05 CA CA3049426A patent/CA3049426A1/en not_active Abandoned
- 2018-01-05 WO PCT/US2018/012689 patent/WO2018129397A1/en not_active Ceased
- 2018-01-05 JP JP2019537110A patent/JP2020514301A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018129397A1 (en) | 2018-07-12 |
| EP3565595A4 (en) | 2021-03-17 |
| US20200040084A1 (en) | 2020-02-06 |
| RU2019124709A3 (enExample) | 2021-12-21 |
| AU2018205272A1 (en) | 2019-07-25 |
| JP2020514301A (ja) | 2020-05-21 |
| CA3049426A1 (en) | 2018-07-12 |
| EP3565595A1 (en) | 2019-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019124709A (ru) | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА | |
| JP2020508655A5 (enExample) | ||
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
| IL299221A (en) | CD3 binding antibodies | |
| JP2017504578A5 (enExample) | ||
| JP2018046872A5 (enExample) | ||
| HRP20181069T1 (hr) | Antagonistička protutijela na il-17 | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| JP2016536322A5 (enExample) | ||
| RU2007139953A (ru) | Антитела к ccr5 и их применение | |
| RU2014100111A (ru) | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| JP2018522888A5 (enExample) | ||
| JP2020514301A5 (enExample) | ||
| AR126758A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| PE20231953A1 (es) | Anticuerpos multiespecificos y combinaciones de anticuerpos | |
| JPWO2021104371A5 (enExample) | ||
| RU2010122044A (ru) | УЛУЧШЕННЫЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Nogo-А И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ | |
| FI4031569T3 (fi) | Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät | |
| JPWO2020014413A5 (enExample) | ||
| JPWO2020014486A5 (enExample) | ||
| JPWO2020014526A5 (enExample) | ||
| RU2021103187A (ru) | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА, НАЦЕЛЕННЫМИ НА CD38 | |
| RU2021103115A (ru) | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА, НАЦЕЛЕННЫМИ НА CCR4 |